Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2017 Jun 17

PMID 28622513

Citations 1178

Affiliations

Soon will be listed here.

Abstract

Liver cancer has the second highest worldwide cancer mortality rate and has limited therapeutic options. We analyzed 363 hepatocellular carcinoma (HCC) cases by whole-exome sequencing and DNA copy number analyses, and we analyzed 196 HCC cases by DNA methylation, RNA, miRNA, and proteomic expression also. DNA sequencing and mutation analysis identified significantly mutated genes, including LZTR1, EEF1A1, SF3B1, and SMARCA4. Significant alterations by mutation or downregulation by hypermethylation in genes likely to result in HCC metabolic reprogramming (ALB, APOB, and CPS1) were observed. Integrative molecular HCC subtyping incorporating unsupervised clustering of five data platforms identified three subtypes, one of which was associated with poorer prognosis in three HCC cohorts. Integrated analyses enabled development of a p53 target gene expression signature correlating with poor survival. Potential therapeutic targets for which inhibitors exist include WNT signaling, MDM4, MET, VEGFA, MCL1, IDH1, TERT, and immune checkpoint proteins CTLA-4, PD-1, and PD-L1.

Citing Articles

QSAR-Based Drug Repurposing and RNA-Seq Metabolic Networks Highlight Treatment Opportunities for Hepatocellular Carcinoma Through Pyrimidine Starvation.

Talubo N, Dela Cruz E, Fowler P, Tsai P, Tayo L Cancers (Basel). 2025; 17(5).

PMID: 40075750 PMC: 11898721. DOI: 10.3390/cancers17050903.

Multi-omics analysis revealed the novel role of NQO1 in microenvironment, prognosis and immunotherapy of hepatocellular carcinoma.

Tang Y, Hu H, Chen S, Hao B, Xu X, Zhu H Sci Rep. 2025; 15(1):8591.

PMID: 40074806 PMC: 11903666. DOI: 10.1038/s41598-025-92700-7.

VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytes.

Naghdi S, Mishra P, Roy S, Weaver D, Walter L, Davies E Nat Commun. 2025; 16(1):2416.

PMID: 40069152 PMC: 11897174. DOI: 10.1038/s41467-025-56898-4.

Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma.

Shiode Y, Kodama T, Sato Y, Takahashi R, Matsumae T, Shirai K Biomark Res. 2025; 13(1):37.

PMID: 40038575 PMC: 11877696. DOI: 10.1186/s40364-025-00752-8.

Strategies for discovering novel hepatocellular carcinoma biomarkers.

Wu S, Zhu L, Feng X, Wang H, Li F World J Hepatol. 2025; 17(2):101201.

PMID: 40027561 PMC: 11866143. DOI: 10.4254/wjh.v17.i2.101201.

References

Karagozian R, Derdak Z, Baffy G . Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014; 63(5):607-17. DOI: 10.1016/j.metabol.2014.01.011. View

Hoshida Y, Nijman S, Kobayashi M, Chan J, Brunet J, Chiang D . Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69(18):7385-92. PMC: 3549578. DOI: 10.1158/0008-5472.CAN-09-1089. View

Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

Jochemsen A . Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin Oncol. 2013; 26(1):114-9. DOI: 10.1097/CCO.0000000000000033. View

Llovet J, Hernandez-Gea V . Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20(8):2072-9. DOI: 10.1158/1078-0432.CCR-13-0547. View

Prieto J, Melero I, Sangro B . Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12):681-700. DOI: 10.1038/nrgastro.2015.173. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K . Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2011; 17(1):72-9. PMC: 3267826. DOI: 10.1634/theoncologist.2011-0386. View

10.

McCarroll S, Kuruvilla F, Korn J, Cawley S, Nemesh J, Wysoker A . Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008; 40(10):1166-74. DOI: 10.1038/ng.238. View

11.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

12.

Lee J, Chu I, Heo J, Calvisi D, Sun Z, Roskams T . Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667-76. DOI: 10.1002/hep.20375. View

13.

Sohn B, Shim J, Kim S, Jang K, Kim S, Kim J . Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res. 2015; 22(5):1256-64. PMC: 5536176. DOI: 10.1158/1078-0432.CCR-15-1447. View

14.

Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard C . Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008; 14(6):471-84. DOI: 10.1016/j.ccr.2008.11.002. View

15.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

16.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

17.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

18.

Kuhn R, Haussler D, Kent W . The UCSC genome browser and associated tools. Brief Bioinform. 2012; 14(2):144-61. PMC: 3603215. DOI: 10.1093/bib/bbs038. View

19.

Lee J, Heo J, Libbrecht L, Chu I, Kaposi-Novak P, Calvisi D . A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410-6. DOI: 10.1038/nm1377. View

20.

Horn S, Figl A, Rachakonda P, Fischer C, Sucker A, Gast A . TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122):959-61. DOI: 10.1126/science.1230062. View